AC Immune (ACIU) Interim CEO Martin Zuegel Buys 77,778 Shares
Martin Zuegel, Interim CEO of ACIU, acquired 33,136 shares on June 11, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Martin Zuegel, Interim CEO at AC Immune SA ($ACIU), bought 77,778 shares on June 11, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $ACIU is up 6.2% after 1 week, up 8.4% after 1 month and up 5.8% to date (from the $2.26 close on Jun 11, 2026).
ACIU
AC Immune SA
Key Points
- On June 11, 2026, Martin Zuegel, Interim CEO of ACIU, purchased 33,136 shares.
- ACIU shares are trading at $2.31, with active institutional interest from BVF Inc/IL and BlackRock, Inc.
- Analysts from BTIG and HC Wainwright maintain a 'buy' rating with price targets of $8 and $12.
Get $ACIU trade alerts by text
We text you when insiders, Congress or big funds trade $ACIU. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated AC Immune SA alert may contain errors. Disclosures
Martin Zuegel, the Interim CEO of ACIU, bought 33,136 shares of the company on June 11, 2026. This insider purchase comes as the stock trades at $2.31 per share.
Other Institutional Activity in ACIU
Institutional investors have been active in ACIU. BVF Inc/IL holds a significant position with 19,822,436 shares valued at about $54.5 million. BlackRock, Inc. increased its stake by 22,109 shares to a total of 524,278 shares worth around $1.44 million. Conversely, Millennium Management LLC decreased its holdings by 140,685 shares, bringing its total to 792,657 shares valued at approximately $2.18 million. Renaissance Technologies LLC also reduced its position by 44,500 shares, leaving it with 624,367 shares worth about $1.72 million.
AC Immune SA Stock Down 10.6%
ACIU shares are trading around $2.31. The company has attracted attention from various institutional investors, indicating active interest in its stock.
Insider Buying and Selling at AC Immune SA
On June 11, 2026, several insiders, including Martin Zuegel, made significant purchases. Zuegel acquired 33,136 shares, while other insiders like Renee Aguiar-Lucander and Carl Howard June also bought shares, with Renee acquiring 38,889 shares and Carl purchasing a total of 55,457 shares.
Analysts Set New Price Targets
Analysts have maintained a positive outlook on ACIU. On March 16, 2026, BTIG reiterated its 'buy' rating with a price target of $8. HC Wainwright & Co. also maintained its 'buy' rating with a higher target of $12. The consensus among analysts remains optimistic, with a strong 'buy' recommendation.
About ACIU
ACIU is a biotechnology company focused on developing treatments for neurodegenerative diseases. It is headquartered in Switzerland and aims to advance medical research in its field. The company collaborates with various partners to bring innovative therapies to market.
Bottom Line
Martin Zuegel's purchase of ACIU shares signals confidence in the company's future. Institutional investors continue to show interest, and analysts maintain favorable ratings. While insider transactions provide insights, they are not necessarily indicative of future stock performance.
Related Filing Alerts
Source: Martin Zuegel's Form 4 filing on $ACIU (Jun 11, 2026). Find the original filing: ACIU Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts